I still think the main component to his appointmen

I still think the main component to his appointment to the board is credibility in the diagnostic capability of MYDX and the use cases for the pen in medical community. Of course we could be totally off and he was brought on board to help with an acquisition bid MYDX received, or a totally separate venture that has note been reported yet. Either way it all looks good as long as the shares are put to good use. Should be a good day for MYDX ... clarity would be appreciated however.